Table 1.
Baseline characteristics
| N = 907 | Vaccine (V) only, n = 535 | Hybrid (H) Immunity, n = 372 | P value, across V and H groups | |
|---|---|---|---|---|
| Age | 53.5 ± 11.7 | 55.5 ± 11.6 | 50.5 ± 11.3 | 0.0001 |
| Female: Male | 5.1:1 | 5.5:1 | 4.7:1 | 0.4 |
| Diagnosis | ||||
| RA | 661 (72.8) | 400 (74.8) | 261 (70.2) | 0.2 |
| Spondyloarthritis | 103 (11.3) | 50 (9.3) | 53 (14.2) | 0.02, 0.6 (0.4–0.9) |
| SLE | 35 (3.8) | 16 (2.9) | 19 (5.1) | 0.1 |
| Vasculitis | 38 (4.1) | 25 (4.6) | 13 (3.5) | 0.3 |
| Other CTDs | 70(7.6) | 44 (8.2) | 26 (6.9) | 0.2 |
| Vaccine Group | ||||
| V + V | 535 (58.9) | 535 (100) | ||
| I + V | 17 (18.7) | 17 (4.6) | ||
| V + I | 25 (2.7) | 25 (6.7) | ||
| I + V + V | 121 (13.3) | 121 (32.5) | ||
| V + I + V | 97 (10.7) | 97 (26.1) | ||
| V + V + I | 112 (12.3) | 112 (30.1) | ||
| Past COVID-19 | 372 (41) | |||
| Time since last event to COVID infection in days | ||||
| Confirmed | 191.4 ± 97.2 | 205 ± 109.5 | 171.9 ± 71.6 | 0.0001 |
| Confirmed + Probable | 186.8 ± 95.8 | 200.2 ± 104.9 | 167.4 ± 77 | 0.0001 |
| Primary Immunization | 0.0001, 1.9 (1.3–2.9) | |||
| AZD1222 | 755 (83.2) | 426 (79.6) | 329 (88.4) | |
| BBV152 | 152 (16.8) | 109 (20.4) | 43 (11.6) | |
| Drugs | ||||
| Methotrexate | 465 (51.3) | 310 (57.9) | 155 (41.7) | 0.0001, 1.9 (1.5–2.5) |
| Sulfasalazine | 164 (18.1) | 124 (23.2) | 40 (10.8) | 0.0001, 2.5 (1.7–3.7) |
| Hydroxychloroquine | 454 (50) | 338 (63.2) | 116 (31.2) | 0.0001, 3.7 (2.9–5.1) |
| Leflunomide | 46 (5) | 38 (7.1) | 8 (2.2) | 0.01, 3.5 (1.6–7.5) |
| Tofacitinib | 56 (6.2) | 41 (7.7) | 15 (4) | 0.03, 1.9 (1.1–3.6) |
| Rituximab | 38 (4.2) | 29 (5.4) | 9 (2.4) | 0.03, 2.3 (1.1–4.9) |
| Tacrolimus | 10 (1.1) | 7 (1.3) | 3 (0.8) | 0.4 |
| Mycophenolate Mofetil | 49 (5.4) | 33 (6.2) | 16 (4.3) | 0.2 |
| Azathioprine | 6 (0.6) | 3 (0.6) | 3 (0.8) | 0.6 |
| TNF inhibitors | 9 (0.9) | 4 (0.6) | 6 (1.6) | 0.1 |
| Glucocorticoids | 105 (11.6) | 71 (13.3) | 34 (9.1) | 0.06 |
V Vaccine, I COVID-19 infection, TNF Tumor Necrosis Factor, RA Rheumatoid Arthritis, SLE Systemic Lupus Erythematosus, CTD Connective Tissue Disease, AZD1222 ChAdOx1 nCoV-19 or AztraZeneca, BNT162b2 Pfizer BioNTech, BBV152 Bharat Biotech